RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20) Save

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

1. Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://bit.ly/2HtYwxg

2. Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs. Also improved COVID medical carehttps://t.co/8aFuVHUDjY

3. QD Video - I'm Not Stupid (IgG4) - Lessons from the clinic. Dr. Jack Cush discusses an IgG4 case and the power of discussion https://t.co/RDIVEeyqxW

4. NEJM reports that obese pts having bariatric surgery have a longer life expectancy (less death HR 0.77; 0.68-0.87; P<0.001) than pts treated w/ nonsurgical, usual obesity care. They live 3 yrs longer (than controls) but 5 yrs shorter than gen Population https://t.co/nBa6IuKAyX

5. Study of seropositivity in RA patients in the RISE (43,581) registry & Marketscan pts (1185) showed ICD10 Coding with M05 had a sensitivity = 0.73- 0.76, & PPV = 0.82 -0.84 for seropositive RA. Good but does that mean Ya'll are miscoding 25% of your RA pts? https://t.co/Wc6FQeQEHA

6. Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics. 86% of incident gout came from C1 & C4 https://t.co/TeMdXx5qU1

7. Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52  https://t.co/n8Mdeonmas

8. SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?  https://twitter.com/RheumNow/status/1318029758588923904

9. Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm

10. Remdesivir FDA Approved for Hospitalized COVID-19

11. Outpatient Visits Return to Pre-COVID Rates

12. High Burnout Rates Among Rheumatologists

13. Back TALK